GSK Completes $950M Acquisition of 35Pharma, Adding Pulmonary Hypertension Drug HS235

summarizeSummary

GSK has completed the acquisition of 35Pharma Inc. for $950 million, gaining HS235, a clinical-stage asset targeting pulmonary hypertension with significant market potential.

check_boxKey Events

• Acquisition Completed

  GSK plc announced the completion of its acquisition of 35Pharma Inc., a private, clinical-stage biopharmaceutical company based in Canada.

• Strategic Asset Acquired

  The acquisition includes HS235, a potential best-in-class molecule for the treatment of pulmonary hypertension (PH), which targets the activin receptor signalling pathway.

• Financial Terms

  GSK acquired 100% of 35Pharma Inc.'s equity for $950 million.

• Market Opportunity

  The global market for PH therapies is forecast to reach $18 billion by 2032, with activin signalling inhibitors expected to account for 50% of this.

auto_awesomeAnalysis

GSK's acquisition of 35Pharma Inc. for $950 million significantly bolsters its Respiratory, Immunology & Inflammation (RI&I) pipeline. The key asset, HS235, targets pulmonary hypertension (PH), a disease with limited treatment options and a large addressable market forecast to reach $18 billion by 2032. HS235 is designed to offer enhanced selectivity, potentially reducing side effects seen with current treatments, and may also provide metabolic benefits. This strategic move positions GSK to capture a share of a growing market with a differentiated therapeutic candidate.